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 Introduction 
Clarithromycin is a relatively new, second-generation, 
semi  synthetic  macrolide  antibiotic  with  a  methoxy 
group  (OCH3)  attached  to  the  C6  position  of 
erythromycin. This derivatization makes clarithromycin 
more acid stable than erythromycin. 
1,2 Clarithromycin 
has broad-spectrum activity against gram-positive and 
gram-negative aerobes, atypical bacterial pathogens of 
the  respiratory  tract,  mycobacterium  species, 
Legionella  and  helicobacter  pylori. 
3  Many  dosage 
forms  of  clarithromycin,  such  as  immediate  and 
extended  release  tablets,  capsules,  dry  suspensions, 
liposome-encapsulated,  microspheres,  cyclodextrin-
compressed and IV formulation have been developed 
due to its wide antibacterial spectrum. 
2,4-9 Nevertheless 
considering adverse effects of oral dosage forms such 
as  gastrointestinal  disorders  and  low  bioavailability 
which doesn’t exceed 55%, and the existence of some 
situations such as unconscious patients for whom the 
only usable dosage form is parenteral form and also the 
absence  of  generic  intravenous  dosage  form  in  Iran, 
there is considerable interest in the development of a 
parenteral formulation of clarithromycin. However, the 
main problem related with clarithromycin intravenous 
form  is  its  practical  insolubility  in  water. 
Clarithromycin  has  the  dimethylamino  moiety  as  the 
only  ionizable  group  (pK8.8)  and  hence  its  aqueous 
solubility at pH 7.0 is only about 500 µg/ml. 
2,10 Using 
binary  systems  with  a  hydrophilic  carrier  by  mixing, 
melting or solvent methods emulsion formulations for 
its IV use have been studied. However, leaving residual 
solvent, thermal  degradation  of  clarithromycin  during 
thermal  sterilization  and  complication  of  these 
processes has limited the application of these methods. 
2,10  Therefore  it  is  necessary  to  develop  a  new 
formulation  to  improve  its  solubility  for  intravenous 
administration  of  clarithromycin. 
11  We  hypothesized 
that  surfactants  and  gluconic  acids  can  enhance 
clarithromycin  solubility. 
10  Based  on  this  hypothesis 
myrj52 and chremophor (in different proportions) and 
lactobionic  acid  were  investigated  and  results  were 
compared and the best formulations were reported. 
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Purpose: The purpose of this paper is to enhance the solubility of clarithromycin (CLR) 
using  nonionic  surfactants  and  some  type  of  acids  for  preparation  of  the  new 
formulations. Methods: Myrj 52 and chremophor (2.5 and 5% w/v) were used in two 
concentrations. To investigate solubility, the formulations were shaken for 48 hours at 
room  temperature.  For  stability  test,  lyophilized  samples  were  maintained  in 
refrigerator at 4° C, and in oven at 40° C. Drug analysis was performed by reverse 
phase  high  performance  liquid  chromatography  (HPLC)  with  ultraviolet  detection. 
Results:  Solubility  tests      indicated  that  lactobionic  acid  was  the  most  effective  to 
increase clarithromycin solubility and chremophor showed higher enhancing effect than 
myrj 52 on CLR solubility. The stability tests results also confirmed that shelf-lives of 
all formulations have been the equivalent to 24 months. Conclusion: On the whole, 
formulations  described  in  this  article  may  be  very  suitable  for  industrial-scale 
manufacturing and clinical application.  
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Materials and Methods   
Materials 
Clarithromycin  (Elder  Nerul,  Pawane  and  Patalg, 
India),  Lactobionic  acid  (Sigma  –  Aldrich,  Co.  St. 
Louis  ,  MO  ,  USA),  Chremophor  (BASF  Florham 
Park, New Jersey), Myrj 52 (Atlas San Diego, USA ), 
Anhydride  citric  acid(Merck  Dermstadt,  Germany), 
Sulfuric  acid  (Merck  Dermstadt,  Germany),  Stearic 
acid (Merck Dermstadt, Germany), Boric acid (Merck 
Dermstadt,  Germany),  Hydrochloric  acid  (Merck 
Dermstadt,  Germany),  Phosphoric  acid  (Merck 
Dermstadt,  Germany),  Salicylic  acid  (Merck 
Dermstadt,  Germany),  NaOH  (Merck  Dermstadt, 
Germany),  Sodium  dihydrogen  phosphate  (Merck 
Dermstadt,  Germany),  Acetonitril  (Merck  Dermstadt, 
Germany),  Tartaric  acid  (Seelze-  Hannover  Riedel  _ 
Dehaen AG , Germany). 
 
Formulation 
To  increase  clarithromycin  solubility  in  water  to 
prepare an injectable solution, above mentioned acids 
were used. Results indicated that lactobionic acid is the 
only acid which can improve drug solubility. Nonionic 
surfactants, myrj 52 and chremophor also were used for 
solubilization.  To  produce  5  formulations,  different 
concentrations of two surfactants were selected, added 
to  appropriate  amount  of  double  distilled  water  and 
were sonicated (Julabo USR 3 Labortechnik, Germany) 
until  complete  dissolution.  Then  500  mg  of 
clarithromycin  was  added  up  and  agitation  was 
continued  for  15  min.  Acid  solution  was  then  added 
and  after  5  minutes  of  stirring,  pH  was  measured 
(Metrohm, Switzerland). Acid addition was continued 
until  a  clear  solution  was  achieved.  However  to 
increase  stability  the  pH  was  kept  above  4.8.  pH  of 
solutions were adjusted using phosphoric acid 85% and 
NaOH 1N in the range of 5 to 6.5. Then the solutions 
were  filtered  through  the  0.22µ  membrane  filter.  To 
prepare  samples  for  stability  tests,  20  vials  of  each 
formulation were prepared. The samples were dried and 
lyophilized for 48 hours in  the freezer  (- 20°C),  and 
then were maintained in refrigerator at 4°C. 
 
Solubility study 
CLA solubility samples were prepared in glass tubes at 
serial  concentrations  for  all  five  solvent  systems 
developed.  For  each  system  ten  glass  tubes  with 
different concentration of drug were prepared. Then the 
samples were shaken for 48 hours at room temperature. 
The  first  tube  in  each  series  in  which  the  fine  un-
dissolved  drug  particles  were  seen,  was  detected  by 
visual  inspection  and  finally  the  range  of  drug 
solubility were determined.  
 
Drug analysis 
A  reverse  phase  high  performance  liquid 
chromatography (HPLC) (Knauer, Germany) analytical 
method  with  ultraviolet  detection  was  employed  for 
drug  analysis.  The  mobile  phase  consisted  of 
acetonitrile-  sodium  dihydrogen  phosphate  (2:3  v/v) 
containing  phosphoric  acid  (3M)  and  NaOH  (1N)  to 
adjust the pH on 4.5. The flow-rate was 2 ml/min and 
the  detection  wavelength  was  set  at  205nm.  Column 
(Shimadzu  C18:250mm×4.6mm,  4µm)  temperature 
was  maintained  at  59°C  using  oven  (Memmert, 
Germany) and the injection volume was 20µL. 
 
Method validation 
In  this  study  a  reverse  phase  HPLC  method  with 
ultraviolet  detection  was  used.  Standard  solutions  of 
3.125 to 50 mg/ml were prepared in water, and linearity 
range  and  correlation  coefficient  were  obtained.  To 
evaluate  the  inter-assay  precision  and  accuracy, 
samples were analyzed for  3 consecutive days,  while 
intra-assay  precision  and  accuracy  were  evaluated 
through  analysis  of  samples  at  three  different 
concentrations  in  the  same  run.  Relative  standard 
deviation  (RSD)  and  the  accuracy  were  calculated 
using the experimental concentration and the nominal 
concentration for each sample. 
 
Stability tests 
To  investigate  the  short-term  storage  stability  of 
clarithromycin in formulations and determine the shelf 
life, at least 6 vials of each formulation were kept for 6 
month  in  undesirable  conditions  including  constant 
relative  humidity  of  75%  and  temperature  of  40
◦  C 
which  equals  maintaining  for  2  years  in  ambient 
conditions. Other lyophilized formulations were kept in 
-20
◦ C. For stability study of newly prepared and ready 
to use injection solution of formulations, a sample of 
each formulation was tested over 120 h at 4
◦ C. 
For  determination  remained  drug  in  formulations, 
monthly a vial from samples in oven and freezer was 
taken  and  was  brought  to  volume  10ml  with  double 
distilled water. Samples were shaken and sonicated for 
5 minutes and injected to HPLC column in triplicate. 
This test was also performed for ready to use solution 
within 5 days. Monthly a calibration curve was taken. 
 
Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry is a rapid and exact 
way to examine drug and excipient compatibility and 
provides  the  most  information  about  possible 
interactions. Samples (5 mg) were sealed in aluminum 
pans and heated at a rate of 20
◦ C per minute from 30
◦ C 
to  300
◦  C  (DSC-60,  Shimadzu,  Japan).  Thermal 
behaviors of clarithromycin and exipients, the complex 
and the physical mixture of them were determined and 
compared. 
 
Results 
To  examine  the  effect  of  different  acids  on  CLR 
solubility,  various  acids  such  as  lactobionic  acid, 
anhydride citric acid, sulfuric acid, stearic acid, boric 
acid, hydrochloric acid, phosphoric acid, salicylic acid 
and tartaric acid were used. Lactobionic  acid showed  
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the best result in improving drug solubility in water and 
forming a  soluble  dosage  form  suitable  for  injection. 
The results obtained for used surfactants, myrj 52 and 
chremophor were illustrated in Table 1.  
 
Table  1.  CLR  solubility  in  the  presence  of  surfactants, 
chremophor and myrj 52 in two concentration levels. 
 
To determine  shelf  lives  of  various  formulations  that 
were kept under undesired conditions for 6 months, and 
also  frozen  samples,  residual  drug  was  determined 
monthly  using  HPLC  method.  Representative 
chromatograms  of  serial  concentration  of 
clarithromycin  were  shown  in  Figure  1.  The  method 
was linear under the reported conditions between 3.125 
and 50 mg/ml with a correlation coefficient of 0.9995. 
Calibration curve was taken monthly. Relative standard 
deviation (RSD) and recoveries were calculated from 
the theoretical and experimental concentrations in order 
to determine the precision and accuracy of the method. 
The  with-in-day  and  day-to-day  RSD  values  were 
determined to be  0 .096 and  0.103 respectively.  The 
accuracy  for  with-in-day  and  day-to-day  were 
determined as 107℅ and 108℅ respectively. The half-
lives  of  various  pharmaceutical  formulations  from 
accelerated  tests  were  obtained  from  division  of  the 
respective area  under  curve  in  the  chromatogram,  on 
the  area  under  the  curve  of  that  concentration  in 
standard  calibration  curve  taken  on  that  month.  The 
consequence results indicated that all formulations had 
shelf  lives  more  than  24  months.  Hence,  it  can  be 
concluded  that  the  formulated  IV  products  had 
sufficient physicochemical stability for storage at room 
temperature for 24 months. Drug remained in various 
formulations kept in oven or freezer, was determined 
monthly and illustrated in Table 2. In order to check the 
stability of drug in ready to use form, the reconstituted 
product was kept for five days in refrigerator (4°C). For 
content analysis, HPLC method was also applied. The 
results indicated that for all formulations remained drug 
after five days were more than 90%. To screen drug 
and  excipient  compatibility,  DSC  was  used  and 
polymorph  types  and  melting  points  of  individual 
substances  were  determined.  The  melting  points  of 
lactobionic acid and myrj 52 were 61.75° C and51.78° 
C  respectively.  The  clarithromycin  endothermic  peak 
temperature  was  228.51°  C,  which  had  not  been 
changed significantly in physical mixture of drug and 
excipients and also in formulations. An example of the 
thermograms of CLR, lactobionic acid and Formulation 
(F2) is given in Figure 2. 
 
Figure1. HPLC chromatograms of different concentration of clarithromycin 
Surfactant  Formulation 
code 
Surfactant 
concentration 
(w/v) 
Solubility 
(mg/ml) 
-  1  -  65-70 
Myrj 52 
2  2.5  70-75 
3  5  75-80 
Chremophor 
4  2.5  75-80 
5  5  80-85  
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Table 2. The percent drug remained in formulations kept in oven or freezer. 
Formulation 
code 
Month 4  Month 5  Month 6 
Oven  Freezer  Oven  Freezer  Oven  Freezer 
1  91.81  96.43  102.9  90.97  98.31  92.69 
2  99.17  95.37  97.99  90.69  102.40  100.84 
3  104.74  98.13  102.63  97.17  101.76  90.96 
4  97.23  105.18  94.92  104.57  90.60  98.11 
5  103.13  96.15  97.13  95.37  105.95  102.77 
 
 
 
 
Figure 2.Thermograms of CLR, lactobionic acid and formulation (F2) kept in the freezer - 20° C for 6 months. 
Discussion 
As  stated  before,  clarithromycin  is  a  drug  that  its 
solubility is very low (0.33 mg/ml) and it is practically 
insoluble  in  water. 
12  Suitable  form  for  intravenous 
injection of clarithromycin is a soluble form. Solubility 
tests for nine different acids with the aim of increasing 
the water solubility of clarithromycin were performed, 
and  lactobionic  acid  found  the  most  effective  to 
increase clarithromycin solubility. In a similar study on 
erythromycin and clarithromycin, lactobionic acid was 
the  best  acid  to  increase  their  solubility 
10,  and  in 
another  study  ascorbic  acid  2-glucoside  improved 
clarithromycin  solubility. 
13  Concerning  the  structural 
similarity  of  erythromycin  with  clarithromycin,  and 
also  the  similarity  of  ascorbic  acid  2-glucoside  and 
lactobionic acid this result seems to be reasonable. On 
the  other  hand  obtained  results  showed  that  drug 
solubility  in  formulations  containing  surfactants  was 
higher than those without surfactants (65-70 mg/ml and 
70-85  mg/ml  respectively).  Myrj  52  with 
concentrations  of  2.5%  and  5%  w/v  could  increase 
CLR solubility 5 and 10 mg/ml respectively. Moreover 
chremophor showed higher enhancing effect than myrj 
52  on  CLR  solubility  (5mg/ml  more  increase  in 
obtained  solubility  using  the  same  concentrations).  It 
has  been  suggested  that  formation  of  the  stronger 
hydrogen bonds in chremophor than myrj is may be the 
reason  of  it’s  tough  emulsification  power. 
10 
Furthermore  DSC  technique  was  used  to  check  the 
compatibility of drug and excipients. As illustrated in 
Figure 2, there is no significant difference in melting 
point peak of clarithromycin in formulations, and pure 
clarithromycin.  This  indicated  that  its  polymorphism 
has not been changed by manufacturing process. From 
the  sample  analysis  point  of  view,  although  previous 
studies have presented several  HPLC  methods with 
electrochemical,  fluorescent,  ultraviolet,  and  mass 
spectrometric detectors for CLA analysis 
8,9,14-17, in the  
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present  study  we  have  developed  a  simple  reverse-
phase  HPLC  method  with  acceptable  precision  and 
accuracy. The results of this study also illustrated that 
(Table 2) shelf-lives of all formulations have been the 
equivalent to 24 months. In previous studies CLR shelf 
life  of  48  months  was  reported. 
18  Hence,  it  can  be 
concluded that the prepared formulations in this study 
have sufficient physicochemical stability for storage at 
-20
◦  C  for  24  months.  There  are  situations  such  as 
kidney  or  liver  failure  or  drug  therapy  in  children, 
where administration of less than a vial dose is needed, 
Therefore  the  storage  of  prepared  solution  and  its 
stability over the storage time is of importance, which 
was  determined  to  be  at  least  120  hours  in  this 
investigation. The acceptance criterion was remaining 
at  least  90%  of  initial  dose  in  the  formulations.  In 
similar studies, the stability of the drug solution, kept at 
2 to 8°C (refrigerator temperature) was reported to be 
24 hours. 
19 Although ready for injection drug solutions 
were stable until 5 days, however for reason of sterility 
consideration,  it  is  recommended  to  limit  the  time 
elapsed between reconstituting and administration to 24 
hours. 
 
Conclusion 
Based  on  obtained  results  using  nonionic  surfactants 
such  as  myrj52  and  chremophor  and  gluconic  acid 
derivatives  like  lactobionic  acid  can  enhance 
clarithromycin  solubility  without  any  complication  in 
manufacturing in industrial scale. The results obtained 
proved  that  clarithromycin  had  sufficient 
physicochemical stability in the prepared formulations. 
Therefore IV dosage form of clarithromycin can be a 
good candidate to be made in an industrial scale.  
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